Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
01/27/2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
|
01/26/2023
A Letter From Our Vice President | January 2023
Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
|
01/26/2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
|
01/26/2023
What Makes AIM’s IMTBC Even More Valuable
AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
|
12/08/2022
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
|
|
11/11/2022
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
|
|
05/25/2022
Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center
Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
|
05/25/2022
FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium
TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
|
05/25/2022
COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma
By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
|
12/04/2021
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients
December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
|
|
Recent Posts
Jan. 27, 2023
Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?
Jan. 26, 2023
A Letter From Our Vice President | January 2023
Jan. 26, 2023
TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium
Jan. 26, 2023
What Makes AIM’s IMTBC Even More Valuable
Jan. 11, 2023